Skip to main content

Table 2 Serum symmetric dimethylarginine (SDMA) measured in healthy horses (non-AKI group), horses at risk of acute kidney injury (high-risk group; divided into horses with colic and horses treated with NSAIDs and gentamicin), and horses with clinically manifest acute kidney injury (AKI group)

From: Detecting acute kidney injury in horses by measuring the concentration of symmetric dimethylarginine in serum

Parameter Non-AKI group (n = 30) High-risk group (n = 30) AKI group (n = 11)
Colic (n = 10) NSAIDs (n = 10) Gentamicin (n = 10) All
Min–max Me (Q1–Q3) n’ Min–max Me (Q1–Q3) n’ Min–max Me (Q1–Q3) n’ Min–max Me (Q1–Q3) n’ Min–max Me (Q1–Q3) n’ Min–max Me (Q1–Q3) n’
SDMA (µg/dL) 10–18 12 (11–14) 2 6–18 12.5 (10.25–14.5) 2 9–14 11 (9.25–11.75) 0 12–15 13 (12–13.75) 0 6–18 12 (11–13) 2 19–62 20 (20–37) 11
  1. Q1, quartile 1; Me, median; Q3, quartile 3. n’, number of horses with values above the upper normal range (> 14 µg/dL) [26]
\